VBI VACCINES INC (VBIV)
CA91822J2020 - Common Stock
Overall VBIV gets a fundamental rating of 3 out of 10. We evaluated VBIV against 588 industry peers in the Biotechnology industry. VBIV may be in some trouble as it scores bad on both profitability and health. VBIV is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year VBIV has reported negative net income.
VBIV had a negative operating cash flow in the past year.
In the past 5 years VBIV always reported negative net income.
VBIV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VBIV's Return On Assets of -107.93% is on the low side compared to the rest of the industry. VBIV is outperformed by 79.69% of its industry peers.
The Return On Equity of VBIV (-1246.79%) is worse than 83.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.93% | ||
| ROE | -1246.79% | ||
| ROIC | N/A |
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VBIV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VBIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VBIV has more shares outstanding
Compared to 5 years ago, VBIV has more shares outstanding
The debt/assets ratio for VBIV is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -11.80, we must say that VBIV is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VBIV (-11.80) is worse than 80.20% of its industry peers.
There is no outstanding debt for VBIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.8 |
ROIC/WACCN/A
WACC9.61%
2.3 Liquidity
VBIV has a Current Ratio of 0.48. This is a bad value and indicates that VBIV is not financially healthy enough and could expect problems in meeting its short term obligations.
VBIV's Current ratio of 0.48 is on the low side compared to the rest of the industry. VBIV is outperformed by 95.05% of its industry peers.
A Quick Ratio of 0.37 indicates that VBIV may have some problems paying its short term obligations.
The Quick ratio of VBIV (0.37) is worse than 95.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
VBIV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2060.47%.
Looking at the last year, VBIV shows a very strong growth in Revenue. The Revenue has grown by 696.61%.
Measured over the past years, VBIV shows a very strong growth in Revenue. The Revenue has been growing by 20.91% on average per year.
EPS 1Y (TTM)-2060.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.5%
Revenue 1Y (TTM)696.61%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Revenue growth Q2Q194.14%
3.2 Future
Based on estimates for the next years, VBIV will show a very strong growth in Earnings Per Share. The EPS will grow by 31.86% on average per year.
The Revenue is expected to grow by 54.28% on average over the next years. This is a very strong growth
EPS Next Y91%
EPS Next 2Y31.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.43%
Revenue Next 2Y54.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VBIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VBIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VBIV's earnings are expected to grow with 31.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.86%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VBIV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VBI VACCINES INC
NASDAQ:VBIV (5/1/2024, 7:00:03 PM)
After market: 0.57 +0 (+0.09%)0.5695
0 (-0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.93% | ||
| ROE | -1246.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-2060.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)696.61%
Revenue growth 3Y101.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y